Europeanhhm

Adrenomed Reveals New Research on Enibarcimab, a Precision Medicine Treatment for Septic Shock, at Weimar Sepsis Update

Saturday, September 09, 2023

Adrenomed AG, a company specializing in vascular integrity, has unveiled new research findings regarding the utilization of enibarcimab for precision medicine in septic shock treatment. These findings stem from a comprehensive analysis of data derived from the phase II clinical trial AdrenOSS-2, which underscores Adrenomed's commitment to developing enibarcimab, a non-neutralizing antibody, as an effective treatment for septic shock.

The analysis reveals a critical breakthrough—the identification of specific biomarkers that can pinpoint patients who derive the most benefit from enibarcimab treatment. These biomarkers include elevated levels of Adrenomedullin (ADM) and low levels of circulating dipeptidyl peptidase 3 (cDPP3).

These groundbreaking findings were presented during the 11th Weimar Sepsis Update by Prof. Matthijs Kox from the Department of Intensive Care Medicine at Radboud University Medical Centre in Nijmegen, The Netherlands. Additionally, they were featured in a poster presentation by the group led by critical care physician Prof. Peter Pickkers in Nijmegen.

The phase II clinical trial, AdrenOSS-2, characterized by its double-blind, randomized, placebo-controlled design, guided by biomarkers, incorporated an in-depth analysis of cDPP3 in conjunction with ADM to effectively identify patients who may not respond optimally to enibarcimab treatment. Elevated cDPP3 levels serve as a warning sign for a heightened risk of organ dysfunction and mortality. This pathway is distinct from the loss of vascular integrity typically associated with septic shock, as evidenced by elevated plasma ADM levels exceeding 70 pg/mL. Notably, the analysis demonstrates that the efficacy of enibarcimab in reducing mortality significantly improves as cDPP3 values decrease. Patients presenting elevated ADM levels but non-elevated baseline cDPP3 (below the upper normal range, ≤ 30-50 ng/mL) experience the most substantial benefit from enibarcimab treatment, with a statistically significant >60% relative reduction in mortality compared to the placebo after 28 days.

Dr. Stephan Witte, Adrenomed's Chief Medical Officer, emphasized the paramount importance of these findings within the realm of precision medicine. He highlighted that the ability to identify treatment-responsive patients through the use of biomarkers represents a pivotal stride towards more effective septic shock treatment.

Dr. Richard Jones, CEO of Adrenomed, expressed optimism regarding enibarcimab's potential to enhance the lives of septic shock patients. He also expressed confidence in its progression toward marketing authorization, based on the compelling clinical data results from the AdrenOSS-2 trial.

 

Source:adrenomed.com

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024